GleamWall
中文EN

TCRT Alaunos Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1107421 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY10.0%
TTM EPS YoY39.1%
Revenue 3-yr CAGR-41.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-121,033.3%
Net margin-120,766.7%
FCF margin—
EBITDA margin-119,966.7%

Returns

ROE-192.0%
ROA-128.4%
ROIC (approx.)-469.9%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio1.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-46.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$3,000$0$0$2,000$4,000
R&D expense$227,000$388,000$427,000$361,000$469,000$185,000$347,000-$86,000
SG&A expense$533,000$564,000$585,000$549,000$718,000$854,000$747,000$845,000
Operating income-$760,000-$952,000-$1.01M-$907,000-$1.19M-$1.04M-$1.09M-$755,000
Interest expense———————$0
Net income-$772,000-$952,000-$1.01M-$893,000-$1.16M-$1.05M-$1.07M-$742,000
EBITDA-$752,000-$943,000-$1.00M-$900,000-$1.19M-$1.04M-$1.09M-$756,000
EPS (basic)-0.31-0.41-0.59—-0.55-0.63-0.67—
EPS (diluted)-0.31-0.41-0.59—-0.55-0.63-0.67—
Weighted avg. shares (diluted)2.60M2.43M1.95M—2.18M1.68M1.60M—
Balance sheet
Cash & equivalents$615,000$124,000$354,000$1.39M$1.94M$2.88M$319,000$1.09M
Receivables$0$0$0$3,000$0$2,000$2,000$5,000
Current assets$1.08M$666,000$970,000$1.99M$2.69M$3.74M$1.07M$2.75M
PP&E, net$66,000$74,000$82,000$91,000$97,000——$0
Total assets$1.92M$1.52M$1.88M$2.97M$3.72M$4.74M$2.12M$2.75M
Current liabilities$947,000$864,000$595,000$813,000$921,000$1.07M$1.06M$692,000
Long-term debt———————$0
Total debt———————$0
Total liabilities$947,000$864,000$595,000$813,000$921,000$1.07M$1.06M$692,000
Shareholders' equity$971,000$652,000$1.29M$2.15M$2.80M$3.66M$1.06M$2.06M
Net debt———————-$1.09M
Shares outstanding3.32M2.49M2.38M2.35M2.21M2.07M1.60M1.60M
Cash flow statement
Operating cash flow-$425,000-$300,000-$1.03M-$552,000-$844,000-$701,000-$772,000-$592,000
Capital expenditure———$1,000———$0
Free cash flow———-$553,000———-$592,000
Investing cash flow———-$1,000———$0
Financing cash flow$916,000——$0$0——$0
Depreciation & amortization$8,000$9,000$8,000$7,000$0$0$0-$1,000
Stock-based compensation$175,000$246,000$141,000$243,000$301,000$184,000$68,000$81,000

Free plan shows the latest 8 periods; Pro shows all 69 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.